Trials / Withdrawn
WithdrawnNCT02380534
Use of Apheretic Technologies in Cardiovascular Disease
Use of H.E.L.P. Apheresis in Patients With High Cardiovascular Disease Lp(a)-Related
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Pavia · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effects of H.E.L.P. apheresis on lipid profile, Lp(a) level, and some inflammatory adypocytokines in patients with high cardiovascular risk.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | H.E.L.P. apheresis | High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year. |
Timeline
- Primary completion
- 2016-02-04
- First posted
- 2015-03-05
- Last updated
- 2022-05-26
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02380534. Inclusion in this directory is not an endorsement.